journal
MENU ▼
Read by QxMD icon Read
search

Alimentary Pharmacology & Therapeutics

journal
https://www.readbyqxmd.com/read/28547755/demographic-and-socioeconomic-influences-on-helicobacter-pylori-gastritis-and-its-pre-neoplastic-lesions-amongst-us-residents
#1
R M Genta, K O Turner, A Sonnenberg
BACKGROUND: Gastric infection with Helicobacter pylori (Hp) can lead to chronic inactive gastritis, atrophy and intestinal metaplasia. AIMS: To investigate in a cross-sectional study these changes among different socioeconomic and ethnic groups within the USA. METHODS: We used the Miraca Life Sciences database, an electronic depository of clinicopathological records from patients distributed throughout the USA, to extract data from 487 587 patients who underwent oesophago-gastro-duodenoscopy with biopsy between 1/2008 and 12/2014...
May 25, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28543334/the-use-of-selective-serotonin-receptor-inhibitors-ssris-is-not-associated-with-increased-risk-of-endoscopy-refractory-bleeding-rebleeding-or-mortality-in-peptic-ulcer-bleeding
#2
S B Laursen, G I Leontiadis, A J Stanley, J Hallas, O B Schaffalitzky de Muckadell
BACKGROUND: Observational studies have consistently shown an increased risk of upper gastrointestinal bleeding in users of selective serotonin receptor inhibitors (SSRIs), probably explained by their inhibition of platelet aggregation. Therefore, treatment with SSRIs is often temporarily withheld in patients with peptic ulcer bleeding. However, abrupt discontinuation of SSRIs is associated with development of withdrawal symptoms in one-third of patients. Further data are needed to clarify whether treatment with SSRIs is associated with poor outcomes, which would support temporary discontinuation of treatment...
May 23, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28543263/randomised-clinical-trial-mesalazine-versus-placebo-in-the-prevention-of-diverticulitis-recurrence
#3
W Kruis, V Kardalinos, T Eisenbach, M Lukas, T Vich, I Bunganic, J Pokrotnieks, J Derova, J Kondrackiene, R Safadi, D Tuculanu, Z Tulassay, J Banai, A Curtin, A E Dorofeyev, S F Zakko, N Ferreira, S Björck, M M Diez Alonso, J Mäkelä, N J Talley, K Dilger, R Greinwald, R Mohrbacher, R Spiller
BACKGROUND: Previous studies have reached conflicting conclusions regarding the efficacy of mesalazine in the prevention of recurrent diverticulitis. AIM: To investigate the efficacy and safety of mesalazine granules in the prevention of recurrence of diverticulitis after acute uncomplicated diverticulitis. METHODS: Two phase 3, randomised, placebo-controlled, double-blind multicentre trials (SAG-37 and SAG-51) investigated mesalazine granules in patients with prior episodes (<6 months) of uncomplicated left-sided diverticulitis...
May 23, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28543549/review-article-recent-insights-into-clinical-decision-making-in-severe-alcoholic-hepatitis
#4
REVIEW
P D J Dunne, E H Forrest
BACKGROUND: Alcoholic hepatitis is a severe acute manifestation of alcoholic liver disease with a high mortality. Management of patients with this condition has been a matter of controversy for many years; however, recent clinical studies have sought to improve the clinical approach to these patients. AIM: To use these recent studies in order to guide clinical management. METHODS: A MeSH search of Medline was performed to specifically identify recent studies which influenced clinical diagnosis, assessment and management of alcoholic hepatitis...
May 21, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28543183/a-novel-k-competitive-acid-blocker-yh4808-sustains-inhibition-of-gastric-acid-secretion-with-a-faster-onset-than-esomeprazole-randomised-clinical-study-in-healthy-volunteers
#5
S Yi, H Lee, S B Jang, H M Byun, S H Yoon, J-Y Cho, I-J Jang, K-S Yu
BACKGROUND: YH4808, a K(+) -competitive acid blocker, is under clinical development for the treatment of acid-related disorders, such as gastroesophageal reflux disease. AIMS: We aimed to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YH4808, compared to placebo and esomeprazole. METHODS: This double-blind, randomised, placebo- and active comparator (esomeprazole)-controlled study was conducted with 123 healthy male volunteers...
May 21, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28524546/inflammatory-bowel-disease-is-presenting-sooner-after-immigration-in-more-recent-us-immigrants-from-cuba
#6
O M Damas, D J Avalos, A M Palacio, L Gomez, M A Quintero, A R Deshpande, D A Sussman, J L McCauley, J Lopez, S J Schwartz, M T Abreu
BACKGROUND: Despite a rising incidence of inflammatory bowel disease (IBD) in Hispanics in the United States, there are no studies examining the relationship between immigrant generation and IBD onset among Hispanics. AIMS: To determine whether age of IBD diagnosis, time from immigration to IBD diagnosis and IBD phenotype, differed across immigration periods in South Florida Cuban immigrants. METHODS: This was a cohort of consecutively identified Cuban-born adults who developed IBD in the United States and were followed in gastroenterology (GI) clinic...
May 19, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28513085/systematic-review-with-meta-analysis-endoscopic-dilation-is-highly-effective-and-safe-in-children-and-adults-with-eosinophilic-oesophagitis
#7
REVIEW
F J Moawad, J Molina-Infante, A J Lucendo, S E Cantrell, L Tmanova, K M Douglas
BACKGROUND: Oesophageal dilation is frequently used as an adjunct treatment to alleviate symptoms that develop from fibrostenotic remodelling in eosinophilic oesophagitis (EoE). Earlier reports described an increased risk of complications associated with dilation. AIM: Perform a systematic review and meta-analysis to assess the efficacy and safety of endoscopic dilation in children and adults with EoE. METHODS: Professional librarians searched MEDLINE, EMBASE, the Cochrane library, Scopus, and Web of Science for articles in any language describing studies of dilation in EoE through December 2016...
May 17, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28504312/g-poem-with-antro-pyloromyotomy-for-the-treatment-of-refractory-gastroparesis-mid-term-follow-up-and-factors-predicting-outcome
#8
J M Gonzalez, A Benezech, V Vitton, M Barthet
BACKGROUND: Gastric peroral endoscopic pyloromyotomy (G-POEM) was introduced for treating refractory gastroparesis. AIM: The presented series focused on clinical mid-term efficacy and predictive outcomes factors. METHODS: This was a single centre study of 29 patients operated on between January 2014 and April 2016, with disturbed gastric emptying scintigraphy (GES) and/or elevated Gastroparesis Cardinal Symptoms Index (GCSI). The procedures were performed as previously described...
May 15, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28497487/systematic-review-with-meta-analysis-the-efficacy-of-vonoprazan-based-triple-therapy-on-helicobacter-pylori-eradication
#9
REVIEW
Y S Jung, E H Kim, C H Park
BACKGROUND: In order to increase eradication rates, vonoprazan, a novel potassium-competitive acid blocker, has been used in Helicobacter pylori eradication therapy. AIM: To summarise the results of the efficacy of vonoprazan-based triple therapy, helping clinicians to better understand the benefit of vonoprazan in the treatment of H. pylori infection. METHODS: We conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords "vonoprazan," "takecab", "TAK-438," "potassium," "competitive," "potassium-competitive," "Helicobacter," and "pylori...
May 12, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28488418/systematic-review-with-meta-analysis-post-operative-complications-and-mortality-risk-in-liver-transplant-candidates-with-obesity
#10
REVIEW
M Barone, M T Viggiani, G Losurdo, M Principi, G Leandro, A Di Leo
BACKGROUND: International guidelines rate class III (morbid) obesity (body mass index [BMI]≥40 kg/m(2) ) as a relative contraindication for liver transplantation (LT) requiring further research. Moreover, data on the mortality risk in candidates with a BMI: 30-34.9 and 35-39.9 kg/m(2) (class I and class II obesity, respectively) are weak. AIM: Herein, we compared post-operative complications and mortality risks in all obese candidates vs candidates with a BMI: 18...
May 10, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28488312/immune-modulator-therapy-for-microscopic-colitis-in-a-case-series-of-73-patients
#11
T G Cotter, A K Kamboj, S B Hicks, W J Tremaine, E V Loftus, D S Pardi
BACKGROUND: Microscopic colitis (MC) is a common cause of chronic diarrhoea. Various treatment options have been described, but there are limited data describing outcomes of corticosteroid-sparing treatments. AIM: To evaluate the outcomes of patients with active MC treated with immune modulators. METHODS: All patients seen at Mayo Clinic, Rochester between January 1, 1997 and November 30, 2016 with a histological diagnosis of MC were identified...
May 10, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28488370/patients-with-cirrhosis-who-have-coronary-artery-disease-treated-with-cardiac-stents-have-high-rates-of-gastrointestinal-bleeding-but-no-increased-mortality
#12
T Krill, G Brown, R A Weideman, D J Cipher, S J Spechler, E Brilakis, L A Feagins
BACKGROUND: Patients with coronary artery disease (CAD) treated with stents require dual antiplatelet therapy (DAPT). For cirrhotics, who often have varices and coagulopathy, it is not clear if the risk of gastrointestinal bleeding (GIB) should preclude use of DAPT. AIM: To compare GIB and mortality rates in cirrhotics with CAD treated medically or with stents. METHODS: Using institutional databases, we identified patients with cirrhosis and CAD treated with stents or medical therapy between January 2000-September 2015...
May 9, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28481042/misbalance-in-type-iii-collagen-formation-degradation-as-a-novel-serological-biomarker-for-penetrating-montreal-b3-crohn-s-disease
#13
W T van Haaften, J H Mortensen, M A Karsdal, A C Bay-Jensen, G Dijkstra, P Olinga
BACKGROUND: Misbalances in extracellular matrix turnover are key factors in the development of stricturing (Montreal B2) and penetrating (Montreal B3) Crohn's disease. AIM: To determine whether serological markers for collagen formation and degradation could serve as biomarkers for complications of Crohn's disease. METHODS: Serum biomarkers for type I, III, V and VI collagen formation (P1NP, Pro-C3, Pro-C5, Pro-C6) and matrix metalloproteinase mediated degradation (C1M, C3M, C5M and C6M) were measured in a retrospective, single centre cohort of 112 patients with Crohn's disease in the terminal ileum (nonstricturing/nonpenetrating: n=40, stricturing: n=55, penetrating: n=17) and 24 healthy controls...
May 8, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28481014/infliximab-and-adalimumab-drug-levels-in-crohn-s-disease-contrasting-associations-with-disease-activity-and-influencing-factors
#14
M G Ward, B Warner, N Unsworth, S-W Chuah, C Brownclarke, S Shieh, M Parkes, J D Sanderson, Z Arkir, J Reynolds, P R Gibson, P M Irving
BACKGROUND: Discriminative drug level thresholds for disease activity endpoints in patients with Crohn's disease. have been consistently demonstrated with infliximab, but not adalimumab. AIMS: To identify threshold concentrations for infliximab and adalimumab in Crohn's disease according to different disease endpoints, and factors that influence drug levels. METHODS: We performed a cross-sectional service evaluation of patients receiving maintenance infliximab or adalimumab for Crohn's disease...
May 8, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28481007/the-influence-of-cyp2c19-polymorphisms-on-exacerbating-effect-of-rabeprazole-in-celecoxib-induced-small-bowel-injury
#15
Y Nuki, J Umeno, E Washio, Y Maehata, A Hirano, M Miyazaki, H Kobayashi, T Kitazono, T Matsumoto, M Esaki
BACKGROUND: Simultaneous use of proton pump inhibitors (PPIs) has been shown to increase the risk of nonsteroidal anti-inflammatory drug (NSAID)-induced small bowel injury. AIM: To investigate whether polymorphisms of the cytochrome P450 2C19 gene (CYP2C19), encoding a key metabolising enzyme for PPIs, are associated with small bowel injury induced by celecoxib in combination with the PPI rabeprazole. METHODS: Study participants included 55 healthy Japanese volunteers, who participated in the PPI-NSAID Kyushu University Study using video capsule endoscopy...
May 8, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28470846/systematic-review-interventions-for-abdominal-pain-management-in-inflammatory-bowel-disease
#16
REVIEW
C Norton, W Czuber-Dochan, M Artom, L Sweeney, A Hart
BACKGROUND: Abdominal pain is frequently reported by people with inflammatory bowel disease (IBD), including in remission. Pain is an under-treated symptom. AIM: To systematically review evidence on interventions (excluding disease-modifying interventions) for abdominal pain management in IBD. METHODS: Databases (MEDLINE, EMBASE, PsycInfo, CINAHL, Scopus, Cochrane Library) were searched (February 2016). Two researchers independently screened references and extracted data...
May 4, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28470881/concentration-dependent-response-to-pioglitazone-in-nonalcoholic-steatohepatitis
#17
M Kawaguchi-Suzuki, F Bril, S Kalavalapalli, K Cusi, R F Frye
BACKGROUND: Pioglitazone is a safe and effective option to manage patients with type 2 diabetes and nonalcoholic steatohepatitis (NASH). However, there is marked variability in treatment response. AIM: To evaluate the relationship between concentrations of pioglitazone and its active metabolites and treatment outcomes in patients with NASH. METHODS: Pioglitazone concentrations were measured in patients with NASH treated with pioglitazone 45 mg/day for 18 months; liver biopsy samples were obtained at baseline and after treatment...
May 3, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28470850/the-frequency-of-acute-kidney-injury-in-patients-with-chronic-hepatitis-c-virus-infection-treated-with-sofosbuvir-based-regimens
#18
R Maan, S H Al Marzooqi, J S Klair, J Karkada, O Cerocchi, M Kowgier, S M Harrell, K D Rhodes, H L A Janssen, J J Feld, A Duarte-Rojo
BACKGROUND: Guidelines recommend withholding sofosbuvir (SOF) in patients with an estimated glomerular filtration rate (eGFR) of less than 30 mL/min. AIM: To assess the risk of acute kidney injury (AKI) in patients with no renal contraindications for SOF-based treatment. METHODS: This multicenter retrospective observational study included all consecutive patients that were treated with SOF-based or telaprevir/boceprevir (TVR/BOC)-based regimens at two tertiary university centers in North America...
May 3, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28470787/the-benefit-of-combination-therapy-depends-on-disease-phenotype-and-duration-in-crohn-s-disease
#19
A N Ananthakrishnan, A Sakuraba, E L Barnes, J Pekow, L Raffals, M D Long, R S Sandler
BACKGROUND: The impact of combination therapy on disease-related morbidity in patients with established Crohn's disease (CD) or ulcerative colitis (UC) remains to be well-defined. AIM: To examine the effect of combination therapy on disease outcomes in CD and UC. METHODS: Using a multicenter prospective cohort, we classified CD and UC patients as being on monotherapy with anti-TNF or on combination with an immunomodulator. The primary outcome was a composite of new IBD-related surgery, hospitalisations, penetrating complications, need for corticosteroids or new biological at 1 year...
May 3, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28464369/systematic-review-with-meta-analysis-risk-factors-for-non-alcoholic-fatty-liver-disease-suggest-a-shared-altered-metabolic-and-cardiovascular-profile-between-lean-and-obese-patients
#20
REVIEW
S Sookoian, C J Pirola
BACKGROUND: The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is closely associated with the co-occurrence of multiple pathological conditions characterising the metabolic syndrome (MetS), obesity in particular. However, NAFLD also develops in lean subjects, whose risk factors remain poorly defined. METHODS: We performed a meta-analysis of 15 studies, along with the data pertaining to our own population (n=336 patients). Data from lean (n=1966) and obese (n=5938) patients with NAFLD were analysed; lean (n=9946) and obese (n=6027) subjects without NAFLD served as controls...
May 2, 2017: Alimentary Pharmacology & Therapeutics
journal
journal
29552
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"